Special Seminar: From Penfield to the Future: Towards The Neuro鈥檚 Next Century

Special Seminar
From Penfield to the Future: Towards The Neuro鈥檚 Next Century

Edward A. Fon, MD, FRCP(C)
Scientific Director, Montreal Neurological Institute-Hospital
Canada Research Chair in Parkinson's Disease
Professor of Neurology and Neurosurgery
Faculty of Medicine and Health Sciences
91黑料网

In person: de Grandpr茅 Communications Centre聽

翱苍濒颈苍别:听

Dr. Edward Fon is the Scientific Director of the Montreal Neurological Institute-Hospital (The Neuro) and Professor in the Department of Neurology and Neurosurgery at 91黑料网. He is a Clinician-Scientist and attending neurologist specializing in movement disorders at the MUHC. He is the Director of the FRQS Quebec Parkinson Network (QPN) and Co-Director of the Canadian Open Parkinson Network (C-OPN). He was trained at the Universit茅 de Montr茅al, 91黑料网 and the University of California, San Francisco (UCSF). His research focuses on the cellular and molecular events leading to neurodegeneration in Parkinson's disease (PD). Dr Fon is particularly interested in the function and cell biology of PD genes. His work has been published in prestigious journals including Nature, Science, Nature Neuroscience, Nature Cell Biology, eLife, Molecular Cell, Physiological Reviews, Neuron, PNAS, PloS Biology, Nature Communications, Journal of Cell Biology, Cell Reports, and EMBO J. As Scientific Director, he has led the implementation of key translational platforms at The Neuro including the Clinical Biological Imaging and Genetic repository (C-BIG) and the Early Drug Discovery Unit (EDDU). To support these programs, he secured major partnerships with public funders and industry while embracing the Open Science Principals of The Neuro. Throughout his career, he has received several awards including the CIHR Clinician-Scientist award, the Prix de Jeune Chercheur Blaise Pascal, a National Scholar award of the FRQS and the EJLB Foundation Scholar. He is currently an elected member of the American Society for Clinical Investigation (ASCI) and a Canada Research Chair (Tier 1) in Parkinson鈥檚 Disease. He is a member of the Research Committee of Brain Canada. His research has benefited from uninterrupted funding throughout his career from the CIHR and is currently supported by Brain Canada, FRQS, the Michael J. Fox Foundation, CQDM, CFI and Parkinson Canada. In 2023, he was listed among the top 1% most cited researchers in the world by Clarivate.